Kura Oncology to Participate in Three Upcoming Investor Conferences
October 30 2023 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that Troy Wilson, Ph.D., J.D., President and Chief Executive
Officer, is scheduled to participate in three upcoming investor
conferences.
- A virtual fireside chat at the TD
Cowen Fall Oncology Innovation Summit: Insights for SITC and ASH
event at 12:00 p.m. ET / 9:00 a.m. PT on November 3, 2023;
- A fireside chat at the Stifel 2023
Healthcare Conference in New York at 11:30 a.m. ET / 8:30 a.m. PT
on November 14, 2023; and
- A fireside chat at the Jefferies
London Healthcare Conference in London at 9:30 a.m. GMT / 5:30 a.m.
ET / 2:30 a.m. PT on November 16, 2023.
Live audio webcasts will be available in the Investors section
of Kura’s website at www.kuraoncology.com, with archived replays
available following all three events.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. The Company’s
pipeline consists of small molecule drug candidates that target
cancer signaling pathways. Ziftomenib is a once-daily, oral drug
candidate targeting the menin-KMT2A protein-protein interaction for
the treatment of genetically defined acute myeloid leukemia (AML)
patients with high unmet need. Kura is currently enrolling patients
in a Phase 2 registration-directed trial of ziftomenib in
NPM1-mutant relapsed or refractory AML (KOMET-001). The Company is
also conducting a series of studies to evaluate ziftomenib in
combination with current standards of care, beginning with
venetoclax/azacitidine and standard induction
cytarabine/daunorubicin chemotherapy in NPM1-mutant and
KMT2A-rearranged newly diagnosed and relapsed/refractory AML
(KOMET-007). Tipifarnib, a potent and selective FTI, is currently
in a Phase 1/2 trial in combination with alpelisib for patients
with PIK3CA-dependent head and neck squamous cell carcinoma
(KURRENT-HN). Kura is also evaluating KO-2806, a next-generation
FTI, in a Phase 1 dose-escalation trial as a monotherapy and in
combination with other targeted therapies (FIT-001). For additional
information, please visit Kura’s website at www.kuraoncology.com
and follow us on Twitter and LinkedIn.
Contacts
Investors:Pete De SpainExecutive Vice President, Investor
Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager, Corporate
Communications(858) 500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024